Introduction
Mitochondrial complex I [nicotinamide adenine dinucleotide (NADH) : ubiquinone oxidoreductase; EC 1.6.5.3] is vital to the energy supply in the body. It is the first enzyme in oxidative phosphorylation (OXPHOS), the process in which breakdown of organic nutrients is coupled to ATP production. Disturbances in complex I function can result in complex I deficiency (OMIM 252 010), which is the most common biochemical defect of the OXPHOS system. It is estimated that OXPHOS disorders occur once in every 5000 newborns (Skladal et al., 2003) , of which complex I deficiency underlies 25-35% (Loeffen et al., 2000; Bugiani et al., 2004; Scaglia et al., 2004; Thorburn, 2004) . It typically features a severe multisystem decline with a poor prognosis, and currently lacks a cure. Although complex I dysfunction initially attracted attention in the context of inherited metabolic disorders, it is now increasingly implicated in diabetes and neurodegenerative disorders such as Parkinson's disease and Alzheimer's disease (Mootha et al., 2003; Eckert et al., 2010; Winklhofer and Haass, 2010) . This makes a better understanding of complex I deficiency of relevance for the general population.
Complex I is the product of seven mitochondrial and 38 nuclear genes (Carroll et al., 2006) . During the past two decades onlymutations in these genes (Calvo et al., 2010) . To explain most of the remaining cases it was inferred that complex I assembly factors must exist analogous to the 20 or more found essential to complex IV assembly. Indeed, in 2002, the first complex I assembly factor was found (Janssen et al., 2002) , and in 2005 the first factor was implicated in complex I deficiency (Ogilvie et al., 2005) . Since then genetic, bioinformatic and proteomic analyses have led to the identification of no less than nine disease-causing assembly factors in only half a decade. Seven of these were found in the past 3 years, promising great growth in the field for the coming years.
In this review, we will address whether these individual discoveries share similarities in terms of function or disease pathology. Furthermore, we will investigate the putative pathological distinction of complex I deficiency caused by mutations in assembly factors versus structural subunits, and highlight therapeutic approaches that may prove particularly effective for assembly disturbances.
Complex I function and deficiency
Complex I is embedded in the mitochondrial inner membrane where it oxidizes the NADH produced during glycolysis, fatty acid oxidation and the Krebs cycle. In more detail, electrons extracted from NADH are funnelled to the electron carrier ubiquinone via a chain of iron-sulphur clusters, resulting in conformational changes that allow proton translocation across the mitochondrial inner membrane (Efremov et al., 2010) . This proton translocation, also performed by complexes III and IV, results in a mitochondrial membrane potential used by complex V (ATP synthase) to generate ATP from ADP and inorganic phosphate (Fig. 1) . Disturbances in the function of complex I can have various physiological consequences, such as disturbed ATP production, oxygen consumption and calcium homeostasis. In addition, it can cause accumulation of reactive oxygen species and lactic acid (Robinson, 2006) , and induce apoptosis (Perier et al., 2005) .
Although there is no obvious genotype-phenotype correlation , several disease phenotypes for complex I deficiency can be distinguished based on inheritance. Mitochondria have their own circular genome, which in humans measures 16 569 bp. In 1988, it first became clear that mitochondrial disorders can be caused by a point mutation or deletion in the mitochondrial genome and that the cell can harbour a mixture of healthy and mutated mitochondrial DNA, called heteroplasmy (Holt et al., 1988; Wallace et al., 1988) . The thousands of copies of mitochondrial DNA are inherited via the mother and randomly Figure 1 The molecular basis and pathology of complex I deficiency. Left: Complex I is part of a system of five enzyme complexes (CI-CV) embedded in the mitochondrial inner membrane, which together perform oxidative phosphorylation. In this system, complex I oxidizes nicotinamide adenine dinucleotide (NADH) to transfer electrons to acceptor ubiquinone via a series of iron-sulphur (FeS) clusters. In turn, this leads to proton translocation across the mitochondrial inner membrane to maintain a proton gradient required for complex V to produce ATP. Complex I is assembled from nuclear subunits translated by cytosolic ribosomes (Ribo) and mitochondrial subunits translated by the mitochondrial ribosome (MitoRibo). Disturbances in the assembly and/or stability of the complex can result in reduced conversion of NADH to NAD + , reduced proton translocation, increased release of reactive oxygen species (ROS), and can ultimately lead to reduced ATP production and the accumulation of lactate. Deficiency of complex I can lead to various cellular abnormalities and apoptosis, which translates into a heterogeneous disease phenotype (right). Affected organs are primarily those with energy-demanding tissue, such as the nervous system, muscle, liver and kidneys. Complex I deficiency is generally an early onset, progressive multisystem disorder featuring severe neurological and muscular problems.
distributed to daughter cells during development in a process called segregation. These characteristics of mitochondrial DNA explain why disorders caused by mutations in the mitochondrial DNA generally feature a high prevalence of mitochondrial symptoms within one family and a high variability in clinical course. In contrast, mitochondrial deficiencies caused by nuclear DNA mutations generally have a much more severe phenotype with early onset. Mammalian complex I has seven mitochondrial genes (ND1-6 and ND4L) and 38 nuclear genes (Carroll et al., 2006) . Mutations in mitochondrial genes are associated with maternally inherited complex I deficiency. The most prevalent pathologies associated with mutations in mitochondrial complex I genes are Leber's hereditary optic neuropathy (OMIM 535 000), mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes (OMIM 540 000) and Leigh syndrome (OMIM 256 000) (Mitchell et al., 2006 ). Leber's hereditary optic neuropathy involves degeneration of retinal ganglion cells and their axons resulting in acute loss of vision. Age of onset is generally between the ages of 15 and 30 years, with males being affected five times more than females (Harding et al., 1995; Yu-Wai-Man et al., 2009) . Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes is a clinically and genetically heterogeneous phenotype of a mostly maternally inherited neurological syndrome. It is characterized by epilepsy or dementia, often with additional neurological symptoms such as migraine or psychiatric problems, lactic acidosis (present in 94% of patients; Hirano and Pavlakis, 1994) , and stroke-like episodes (hemianopia, hemiparesis, aphasia and hemineglect, etc.), associated with additional symptoms such as epileptic seizures, ataxia, migraine-like headaches, impaired vision or hearing, or disturbances in consciousness (Finsterer, 2009) . Leigh syndrome is a devastating neurodegenerative disease (OMIM 256 000; Loeffen et al., 2000) . Most of the cases typically present within the first 2 years of life with psychomotor retardation in combination with signs of brainstem or extrapyramidal dysfunction and lactic acidaemia, usually in a period of increased stress, such as infection (Rahman et al., 1996; Finsterer, 2008) . Other symptoms include neurological symptoms (ophthalmoparesis, optic atrophy, ataxia, dysphagia, cranial nerve palsies, muscle weakness, hypotonia, dystonia, respiratory impairment, lethargy and polyneuropathy) whether or not in combination with dysmorphic features, endocrine abnormalities, hypertrichosis, short stature, cardiac abnormalities (hypertrophic or dilated cardiomyopathy) or gastrointestinal problems (diarrhoea), diabetes, vomiting, anaemia or renal problems. Death usually occurs within the first years of life as a consequence of respiratory failure caused by ongoing brainstem dysfunction, which can be accompanied by increasing muscle weakness (Finsterer, 2008) .
Mutations in nuclear genes show Mendelian inheritance. The majority (26%) of patients with mutations in nuclear complex I genes present with Leigh syndrome. Other phenotypes associated with mutations in nuclear complex I genes include neonatal cardiomyopathy with lactic acidosis, leucoencephalopathy and other undefined progressive or stable encephalomyopathies. Neonatal cardiomyopathy with lactic acidosis involves a relatively common early onset, progressive hypertrophic cardiomyopathy leading to death usually within the first year of life (Loeffen et al., 2000; Bugiani et al., 2004 ). Leucoencephalopathy has been described with a progressive occurrence of large cavitations in subcortical white matter, accompanied by ventricular enlargement and macrocephaly. The neurological condition comprises involuntary movements and signs of brainstem involvement, developmental regression, failure to thrive and spasticity (Bugiani et al., 2004; Hoefs et al., 2010) .
Complex I assembly factors: a novel cause for disease
Sequencing of the seven mitochondrial DNA-encoded and 38 nuclear DNA-encoded complex I genes could provide a genetic explanation for 550% of the patients. This made clear that the cause of many disease cases must be sought outside the structure of complex I. Prime suspects were complex I assembly factors, analogous to those identified for complex IV in the yeast model organism (Fontanesi et al., 2006) . Assembly factors aid assembly of a complex without being part of the final structure. Although the lack of complex I in yeast initially hampered their identification, pioneering work in the fungus Neurospora crassa delivered the first two complex I assembly factors, called CIA30 and CIA84 (Kuffner et al., 1998) . The human orthologue of CIA30, NDUFAF1, proved essential to human complex I assembly and mutations in the gene were linked to complex I deficiency (Vogel et al., 2005; Dunning et al., 2007) .
Lacking additional genetic pointers to go on, homozygosity mapping in consanguineous families was key to finding human complex I assembly factors. Some new factors were found simply by sequencing all candidate genes in homozygous regions (e.g. C20orf7 and NDUFAF4) (Sugiana et al., 2008; Saada et al., 2008) . Additional clues for identifying new complex I disease genes have come from recent developments in high-throughput analysis of gene and protein function.
One example is proteomics. A liquid chromatography-mass spectrometry-based method to profile protein interactions with complex I assembly intermediates delivered NDUFAF3 , and simultaneous homozygosity mapping followed by sequencing implicated the NDUFAF3 gene in complex I deficiency (Saada et al., 2009) . Additional proteomic strategies, such as blue native-polyacrylamide gel electrophoresis and tandem affinity purification, illustrated binding of NDUFAF3 with previously identified assembly factor NDUFAF4 from early to late stages of complex I assembly (Saada et al., 2009) . Tandem affinity purification was combined with mass spectrometric analysis to find proteins binding to NDUFAF1, which provided the ECSIT and ACAD9 assembly factors (Vogel et al., 2007c; Nouws et al., 2010) . Both factors were previously implicated in other cellular processes than OXPHOS (Kopp et al., 1999; Zhang et al., 2002; Xiao et al., 2003) . ACAD9 mutations turn out to be an important cause for complex I deficiency, as recently three research groups identified pathogenic mutations in the ACAD9 gene in 10 patients (Haack et al., 2010; Nouws et al., 2010; Gerards et al., 2011) . The examples above show the strength of combining homozygosity mapping with proteomic approaches to verify or direct identification of new assembly factors.
Another example is bioinformatics. Benefiting from the fact that yeast does not have complex I and other organisms do, subtractive genome analysis provided assembly factor NDUFAF2 (Ogilvie et al., 2005) . This protein is a paralogue of complex I subunit NDUFA12 and is associated with a late-stage assembly intermediate. The NDUFAF2 gene proved an important source of disease-causing mutations associated with complex I deficiency (Ogilvie et al., 2005; Barghuti et al., 2008; Hoefs et al., 2009; Janssen et al., 2009; Calvo et al., 2010; Herzer et al., 2010) . Innovations in the computation of large data sets allowed for more expansive, genome-wide bioinformatic approaches. Pagliarini et al. (2008) combined in-depth protein mass spectrometry, microscopy and machine learning to generate a compendium of 1098 mitochondrial genes, which was further used in conjunction with phylogenetic profiling to develop a list of 19 putative complex I disease-causing genes. A pathogenic mutation in C8orf38 was found after subsequent homozygosity mapping. High-throughput pooled sequencing in a complex I-deficient patient cohort identified mutations in both FOXRED1 and NUBPL (Calvo et al., 2010) . NUBPL, also known as huInd1, plays a role in iron-sulphur cluster incorporation during early complex I assembly (Sheftel et al., 2009) . A second patient harbouring mutations in FOXRED1 was reported shortly after (Fassone et al., 2010) , but the exact function of the protein remains unclear.
The role of assembly factors during complex I assembly
Human complex I assembly has primarily been studied by investigating the accumulation of assembly intermediates either in patient cell lines or after inhibition of mitochondrial translation, and by tracing 35 S or epitope labelled complex I subunits during the assembly process (Antonicka et al., 2003; Ugalde et al., 2004; Lazarou et al., 2007; Vogel et al., 2007a; Perales-Clemente et al., 2010) . This has led to the identification of multiple assembly intermediates. For example, tracing the NDUFS3 subunit during assembly revealed at least six assembly intermediates (Vogel et al., 2007b) . In addition, at least five entry points were recently identified for mitochondrial DNA-encoded subunits (PeralesClemente et al., 2010) . Based on the temporal order of appearance and the composition of reported assembly intermediates a basic assembly scheme can be devised (Fig. 2 , subcomplex numbers based on Vogel et al., 2007b) . Briefly summarized, a complex of several core nuclear DNA-encoded subunits is formed and tethered to the mitochondrial membrane during early assembly (Fig. 2,  subcomplexes 1, 2 and 3) . In parallel, hydrophobic membrane complexes are formed and incorporated into the maturing complex (Fig. 2 , at subcomplexes 4 and 5). Subsequent expansion of the complex includes addition of subunits from the dehydrogenase module (Fig. 2, subcomplex 6 ), resulting in fully assembled complex I (Fig. 2, complex 7) .
Altogether, nine assembly factors have been implicated in complex I deficiency in a short period of time (Fig. 2) . Currently, the precise mechanism of action of most complex I assembly factors is unclear. An exception is NUBPL, which is required for the incorporation of iron-sulphur clusters (Sheftel et al., 2009) , present in six subunits (NDUFV1, NDUFV2, NDUFS1, NDUFS2, NDUFS7 and NDUFS8). Despite the lack of mechanistic data, the stages in which the other assembly factors operate can be derived from the accumulation of assembly intermediates upon their mutation or knockdown, and by examining their protein-protein interactions by affinity purification. The proposed involvement of each factor during assembly is summarized in the scheme in Fig. 2. 35 S labelling of mitochondrial protein showed that mutations in C20orf7 lead to the accumulation of early membrane subcomplexes, suggesting that C20orf7 acts in early assembly (Sugiana et al., 2008) . However, as C20orf7 mutations have also been implicated in combined complex I/complex IV deficiency, its role may not be exclusive to complex I assembly (Saada et al., 2011) . NDUFAF1 and ACAD9 have been found in conjunction with assembly factor ECSIT, and NDUFAF1 was reported to associate with a number of complex I subunits (Dunning et al., 2007; Vogel et al., 2007c; Nouws et al., 2010) . Knockdown of any of these assembly factors results in accumulation of subcomplexes 4 and 5 (Fig. 2) , hinting towards a role in the incorporation of membrane subunits. Epitope tagging of assembly factors NDUFAF3 and NDUFAF4 revealed their association with each other and with assembly stages 3, 4, 5 and 6, indicating a role from early to late complex I assembly (Saada et al., 2009) . NDUFAF2 is typically observed in an accumulated near holocomplex upon mutation of subunits NDUFV1 or NDUFS4 (Ogilvie et al., 2005 , Vogel et al., 2007a , indicating that it is involved in late assembly or complex I stability. Putative associations of assembly factors C8orf38 and FOXRED1 with complex I subunits have not been studied. An additional protein, apoptosis inducing factor, has been implicated in complex I deficiency in mouse studies (Vahsen et al., 2004; Joza et al., 2005) , but as mutations in human patients resulted in a combined complex III/IV deficiency and mitochondrial DNA depletion, its requirement for complex I assembly is as yet, ambiguous (Ghezzi et al., 2010) . In summary, most identified assembly factors are involved in early assembly, more specifically the incorporation of hydrophobic membrane subunits (NDUFAF1-possibly in combination with ACAD9 and ECSIT, NDUFAF3 and NDUFAF4 and C20orf7). Apparently this is a process that requires careful coordination, akin to the incorporation of prosthetic groups during complex IV assembly (Fontanesi et al., 2006) .
The pathology of assembly factors
Do mutations in complex I assembly factors result in a unique pathology? At first glance the symptoms listed in Table 1 are not distinct from what is observed for previously reported complex I deficiencies. It should be noted that making a distinction based on symptoms is complicated by possible differences in their classification between different case reports. In addition, the same mutation can lead to different clinical outcomes. For example, reported consanguineous siblings carrying ACAD9 and NDUFAF3 mutations may have had a similar age of onset and symptoms, but siblings with the same NDUFAF4 mutation had a considerable difference in the development of symptoms. Also, mutations in the same gene can lead to different clinical outcomes. For example, one patient carrying a mutation in C20orf7 died after 7 days of high blood lactate level. Two siblings harbouring another mutation in C20orf7 are both in their 20s and diagnosed with Leigh syndrome. After puberty the progression of the disease stopped.
A notable observation is the vanishing white matter reported for almost all patients with NDUFAF2 mutations. This brain anomaly has previously been reported for a mutation in a structural complex I subunit that is incorporated late in the assembly pathway (Pagniez-Mammeri et al., 2010), the stage in which NDUFAF2 is also active. Other gene-pathology relationships are less transparent. ACAD9 and NDUFAF1 were shown to be co-dependent and to be active in the same assembly stages. Mutations in either factor are associated with a high incidence of exercise intolerance and cardiomyopathy. In contrast, two other proteins known to interact in the assembly pathway are NDUFAF3 and NDUFAF4, Figure 2 The dawn of complex I assembly factors. The histogram (top) gives a historical overview of the cumulative number of unique mutations associated with complex I deficiency in nuclear DNA-encoded subunit genes (nDNA subunits), mitochondrial DNA-encoded subunit genes (mtDNA subunits) and assembly factors. Mitochondrial DNA mutations were included when the mutations were scored 510 by use of the Mitchell scoring table (Mitchell et al., 2006) . The more recently published mutations were included in the chart when these were proven to be pathogenic by the creation of cybrids or they had to fulfil three of the four following criteria: (i) absence of the mutation in 5100 controls; (ii) presence of heteroplasmy; (iii) a highly conserved amino acid was changed; and (iv) the mutation segregated with disease. The mutations and the corresponding references are listed in Supplementary Table 1. Bottom: The proposed involvement of each disease-implicated assembly factor in the assembly process is indicated with arrows. Numbers of subcomplexes refer to those described in Vogel et al. (2007b) . This table encompasses all published case reports. Boxes in black indicate the symptom was reported in the original article; white boxes indicate the symptom was absent or not tested in the original article. CI = complex 1; CH = compound heterozygous. ND = not determined; Residual CI activity in fibroblasts = complex I activity normalized for COX activity, percentage of lowest control value (values in bold are normalized to citrate synthase); Yellow box = percentage of control mean.
Residual CI activity in muscle = complex I activity normalized for citrate synthase activity, percentage of lowest control value; # = determined by in gel activity; d = days; w = weeks; m = months; y = years. Brain abnormalities = on MRI or CT and/or diagnosed brain dysfunction. N = not dead, age at report date. 1 = Hemizygous for c.182C 4 T mutation, probably the other allele was deleted. Elevated alanine level = in blood; except for 2 = in urine. The patient number, as mentioned in the case report, is given in brackets.
yet apart from high lactate levels the symptoms deviate. Despite NUBPL's seemingly crucial role in complex assembly, the patient carrying a mutation in the gene is 8 years old and suffering from encephalopathy but no other organs are affected. In summary, given the small number of mutations found it is not yet possible to relate an individual assembly factor gene to a specific clinical phenotype, nor to make a clear distinction from mutations in nuclear subunit genes. However, when we analyse mutations in assembly factor genes as a separate class we noted that disorders caused by mutations in assembly factors (versus nuclear complex I subunit genes) generally result in a significantly later age of death, which becomes prominent after 12 months of life (Fig. 3) . Although the age of onset is reported to differ between complex I deficiency caused by mutation in nuclear versus mitochondrial complex I genes (Swalwell et al., 2011) , we found no apparent difference in the age of onset between complex I deficiency caused by mutations in complex I nuclear subunit genes versus complex I assembly genes (Fig. 3) .
Clinical perspectives
Current therapeutic strategies for complex I deficiency can relieve symptoms, but are unable to cure or even delay the progress of the disease. General approaches include administration of vitamins and cofactors, such as different forms of ubiquinone (Q10), even though beneficial effects are unclear because proper clinical trials are scarce (Chinnery et al., 2006; Glover et al., 2010; Kerr, 2010) .
Fortunately several encouraging new approaches are being developed, some of which may prove particularly useful for the treatment of complex I deficiency caused by disturbances in the assembly process. The assembly process can be viewed as a multistep reaction that involves input of subunits, catalysis by assembly factors and output of a holoenzyme. Mutations in assembly factors generally slow down or halt the reaction even though the subunits are without error. With this notion in mind, to restore assembly, one could either improve the function of any residual mutated assembly factor or increase the flow of substrates into the assembly 'reaction'. Of note, the success of such strategies will depend on the relative contribution of the assembly factor to the assembly process and the functional impact of the mutation.
Stabilization of assembly factors can be achieved by targeted administration of cofactors. For example, a high dosage (300 mg/day) of riboflavin increased complex I activity and improved the clinical condition of patients with the ACAD9 mutation (Gerards et al., 2011) . Furthermore, riboflavin was reported to stabilize the FAD group in complex I assembly protein, apoptosis inducing factor (Ghezzi et al., 2010) . Likewise, this strategy has been reported to work for destabilized subunits, as the effects of a mutation of NDUFV1 could be alleviated by riboflavin supplementation (Benit et al., 2001) .
Increasing the amount of substrate (the subunits) to partly restore assembly is another promising strategy. Activation of PPAR (peroxisome proliferator-activated receptor) and PGC-1 transcriptional pathways led to increased mitochondrial biogenesis and improved mitochondrial physiology in cellular models for OXPHOS deficiency (Srivastava et al., 2007) . More importantly, PGC-1 overexpression led to a significant improvement in endurance and healthy life span of a mouse knockout of complex IV assembly factor COX10 (Wenz et al., 2008) . Administration of PPAR panagonist bezafibrate to the diet of these mice had a similar effect. As another example, overexpression of transcriptional activator NF-Y could partially rescue complex IV deficiency caused by mutation in assembly factor SURF1 by increasing complex IV expression (Fontanesi et al., 2008) . Metabolic sensor kinases such as metabolic sensor kinase mTOR can also induce mitochondrial biogenesis (Cunningham et al., 2007) . Recently, D'Antona et al. (2010) showed that mTOR stimulation with branched chain amino acids elevated mitochondrial biogenesis in middle-aged mice and up-regulated the reactive oxygen species defence mechanism. The quality control system, which includes molecular chaperones such as heat shock proteins and the ubiquitin proteasome, plays a key role in certain neurodegenerative diseases and cancer. Prevention of aggregation of misfolded proteins via small molecular regulators, chemical chaperones or neutraceuticals provides therapeutic options for treatment of Alzheimer's disease and Parkinson's disease (Wisniewski and Sadowski, 2008; Ali et al., 2010; Rose et al., 2011) . Likewise, a similar approach to prevent aggregation of assembly intermediates may prove a useful tool to treat mitochondrial diseases caused by mutations in assembly factors. A direct link between protein aggregation and disease pathology has not yet been established for complex I deficiency. However, disturbances in mitochondrial protein quality control have been implicated in respiratory deficiency. For example, mutations in the m-AAA protease component AFG3L2 lead to respiratory deficiency and spastic paraplegia (Di Bella et al., 2010) .
Conclusion
The rapid emergence of complex I assembly factors has had several implications. It provided a genetic solution for part of the thus far unexplained disease cases, aiding diagnosis and prevention. The recent identification of multiple assembly factors working in similar assembly stages has helped to direct future research into the molecular basis of disease. By analogy to complex IV for which 420 assembly factors aid assembly of a 13 subunit complex, 10-20 new complex I assembly factors are expected to be found in the next couple of years. This search is greatly facilitated by implementation of technical novelties, such as high-throughput bioinformatic screening and whole genome sequencing.
Although highly desirable, the clinical heterogeneity of complex I deficiency may preclude a general therapeutic approach. Most likely tailored combinations of approaches will provide the most effective personalized medicine. Several therapeutic options are being developed to alleviate disturbed complex I biogenesis. A prerequisite to further develop these approaches is detailed mechanistic knowledge of the molecular basis of disease. Therefore, it is of the utmost importance to accompany the association of new mutations with disease by detailed functional analysis of the involved assembly factor.
